Skip to content

BIVIT

Active
Public limited companyfounded 198936 yrs activeWestlaan 14, 8560 Wevelgem, BelgiumKBO/BCE: BE 0439.165.025
Summary

BIVIT has been active since 1989 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €780,157 and a net result of €368,404. Equity remains stable across the filed fiscal years (±0.5% per year). Its solvency ranks better than 16% of 79 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Risk analysisWatch ReportCompare
BIVITActiveChecked score 81/100
Risk analysis ReportCompare

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201Manufacture of food products NACE 10910NACE 15710
1 site
Size
€4.4mtotal assets 2025
Staff
23.5 FTE
Equity
€780,157
Profit
€368,404
Financial health
81 Excellent Checked score 2025
Bankruptcy chance 12 m
0.4%
Structure
Parent
PALACON · 99%
Accounts 1 d early0 of 7 deeds read
Why 81- Liquidity: current ratio 1.09, cash €118,505- Equity €780,157 (17.8% of total assets)- Size: 23.5 FTE, total assets €4.4m+ Profit of €368,404 (FY 2025)Show the evidence

Checked score

Score 2025
81 / 100
Excellent
Probability in this band: under 0.55%
Better than 31% of its sector peers (NACE 21, small)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 43-1
equity 17.8% of total assets
Liquidity 22+4
short-term debt 59.8% · cash 2.7%
Profitability 79-2
return on assets 8.4%
Bankruptcy probability, 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (43 companies)
Last 17 months 06-2025: 0.3%lowest value 07-2025: 0.5%▲ +38.6% vs 06-2025highest value 08-2025: 0.3%▼ -27.0% vs 07-2025 09-2025: 0.3%● 0.0% vs 08-2025 10-2025: 0.3%● 0.0% vs 09-2025 11-2025: 0.3%▲ +3.0% vs 10-2025 12-2025: 0.3%● 0.0% vs 11-2025 01-2026: 0.3%● 0.0% vs 12-2025 02-2026: 0.3%● 0.0% vs 01-2026 03-2026: 0.4%▲ +1.4% vs 02-2026 04-2026: 0.4%▲ +4.8% vs 03-2026 05-2026: 0.4%▲ +1.9% vs 04-2026 06-2026: 0.4%▲ +3.4% vs 05-2026 07-2026: 0.4%▲ +2.3% vs 06-2026 08-2026: 0.4%▼ -1.3% vs 07-2026 09-2026: 0.4%● 0.0% vs 08-2026 10-2026: 0.4%● 0.0% vs 09-2026
  • Liquidity: current ratio 1.09, cash €118,505 raises the probability
  • Equity €780,157 (17.8% of total assets) raises the probability
  • Size: 23.5 FTE, total assets €4.4m raises the probability for this profile
  • Profit of €368,404 (FY 2025) lowers the probability
Credit up to €60,000 at 30 days acceptable
Liquidity tight (current ratio 1.09 against 1.1 in 2024; short-term debt: 59.8% and cash: 2.7% of total assets), and 82.2% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 21, small). Better than this share of them on solvency 9%, liquidity 12%, profitability 70%, growth against the median 35%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Liquidity: current ratio 1.09, cash €118,505
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
raises risk · Equity €780,157 (17.8% of total assets)
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
raises risk · Size: 23.5 FTE, total assets €4.4m
In the bankruptcy model this factor raises the probability for this profile.
NBB · annual accounts
lowers risk · Profit of €368,404 (FY 2025)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 79 sector peers (2025).
NBB · sector comparison
Position among 79 sector peers
Solvency
better than 16%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
1 d early
2024
on the day
2023
61 d early
2022
31 d early
2021
72 d early
2020
30 d early
2019
33 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 23 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 30 June (4 of the last 5 filed years within 31 days of that day).
Companies Code · seven months
Position in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · full…
  2. Annual accounts filedfiscal year 2024 · abbreviated…
  3. Annual accounts filedfiscal year 2023 · abbreviated…

Key points

  • Caution: Among the weakest 17% on solvencysector median 48.4% · 79 companies 17.8% View
  • Positive: 8 profitable years in a rowprofit 2025: €368,404 8 years View
  • Controlled by PALACON 99% View
  • Positive: Always filed on timeaccounts within the deadline every year 6 years View

By topic

Financials

Fiscal year
2025
Total assets
€4.4m
Profit
€368,404
Solvency
17.8%
Total assets▲ 5.7%
Net result
20182025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-07-2027
  1. 30-07-2026Annual accounts filed
  2. 31-07-2025Annual accounts filed
  3. 31-05-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Founded
21-12-1989
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure